AngioSoma announces that it is filing new improvements to its US Patent No. 5,728,129 and five predecessor patents 4,850,957; 4,994,067; 5,087,265; and 5,695,519; all of which will be used as “prior art” to its newest catheter, the OmniCath 2.
With the new improvements being added, the OmniCath 2 may be the most versatile debulking and vessel remodeling atherectomy catheter available for endovascular interventional procedures in treating coronary and peripheral artery diseases resulting in plaque-atherosclerosis. The new improvements include:
a plaque cutting mechanism that allows cutting from either (a) the end-tip to first recanalize the blocked lumen, then (b) a further step of completely debulking the lesion using the directional side-window;
discrete angioplasty balloon proximal (upstream) to blood flow allowing for second step angioplasty and vessel wall remolding;
using the same balloon for optional upstream blocking of blood flow allowing simultaneous saline irrigation and clear endoscopic view from the side-cutting window or most distal tip, or for video feed giving the operator/physician precise visual control; and
completely detachable and disposable catheter shaft, driveline, cutter, and angioplasty balloon from motor assembly preventing cross contamination of infections such as MRSA while allowing reuse of its lithium battery powered motor.
Per CEO Alexanderia K. Blankenship, “The OmniCath 2 will be priced competitively with both balloon catheters and atherectomy devices providing physicians with a multiplicity of easy options.” The company estimates that it may be able to achieve sales of over $1 billion annually when fully integrated into the market.
AngioSoma is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ('PAD').
Our lead pharmaceutical product Liprostin, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration ('FDA') approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.